

## Datasheet

### UBE3A monoclonal antibody (M01), clone 2F6

**Catalog Number:** H00007337-M01

**Regulatory Status:** For research use only (RUO)

**Product Description:** Mouse monoclonal antibody raised against a partial recombinant UBE3A.

**Clone Name:** 2F6

**Immunogen:** UBE3A (AAH09271, 51 a.a. ~ 150 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

**Sequence:**

ETFQQLITYKVISNEFNSRNLVNDDDAIVAASKCLKMVY  
YANVVGGEVDTNHNEEDDEEPIPESELTLQELLGEE  
RRNKKGPRVDPLETELGVKTLDCR

**Host:** Mouse

**Reactivity:** Human, Rat

**Applications:** ELISA, IF, IHC-P, S-ELISA, WB-Ce, WB-Re

(See our web site product page for detailed applications information)

**Protocols:** See our web site at

<http://www.abnova.com/support/protocols.asp> or product page for detailed protocols

**Isotype:** IgG2a Kappa

**Storage Buffer:** In 1x PBS, pH 7.4

**Storage Instruction:** Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

**Entrez GeneID:** 7337

**Gene Symbol:** UBE3A

**Gene Alias:** ANCR, AS, E6-AP, EPVE6AP, FLJ26981, HPVE6A

**Gene Summary:** This gene encodes an E3 ubiquitin-protein ligase, part of the ubiquitin protein

degradation system. This imprinted gene is maternally expressed in brain and biallelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman Syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies. The protein also interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumor protein p53. Alternative splicing of this gene results in three transcript variants encoding three isoforms with different N-termini. Additional transcript variants have been described, but their full length nature has not been determined. [provided by RefSeq]

**References:**

1. The E6 proteins from multiple beta HPV types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA. J Virol. 2008 Nov;82(21):10408-17. Epub 2008 Aug 20.